US EditionGeneCentric Advances Precision Oncology With New Liquid Biopsy Platform - Data Intelligence
Summary by Plato. Vertical Search. Ai. | PlatoAiStream. Data Intelligence. Vertical Search. Ai.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
GeneCentric Advances Precision Oncology With New Liquid Biopsy Platform - Data Intelligence
GeneCentric Therapeutics has secured $8m in new funding to accelerate the development of its RNA-based liquid biopsy platform, a diagnostic technology aimed at transforming cancer care through non-invasive tumour profiling. The platform is designed to improve treatment selection, monitor disease progression, and detect resistance mechanisms by analysing gene expression signatures from a simple blood draw. Unlike traditional tissue biopsies, whic…
GeneCentric advances precision oncology with new liquid biopsy platform
GeneCentric Therapeutics has secured $8m in new funding to accelerate the development of its RNA-based liquid biopsy platform.The post GeneCentric advances precision oncology with new liquid biopsy platform appeared first on Medical Device Network.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium